Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer
Open Access
- 7 October 2009
- journal article
- Published by Springer Science and Business Media LLC in Breast Cancer Research
- Vol. 11 (5), R73
- https://doi.org/10.1186/bcr2409
Abstract
MUC1 is a cell-surface glycoprotein that establishes a molecular barrier at the epithelial surface and engages in morphogenetic signal transduction. Alterations in MUC1 glycosylation accompany the development of cancer and influence cellular growth, differentiation, transformation, adhesion, invasion, and immune surveillance. A 20-amino-acid tandem repeat that forms the core protein of MUC1 is overexpressed and aberrantly glycosylated in the majority of epithelial tumors. AS1402 (formerly R1550) is a humanized IgG1k monoclonal antibody that binds to PDTR sequences within this tandem repeat that are not exposed in normal cells. AS1402 is a potent inducer of antibody-dependent cellular cytotoxicity (ADCC), specifically against MUC1-expressing tumor cells. The objective of this study was to determine the safety, tolerability, and pharmacokinetic (PK) characteristics of AS1402 monotherapy in patients with locally advanced or metastatic MUC1-positive breast cancer that had progressed after anthracyclines- and taxane-based therapy.This publication has 19 references indexed in Scilit:
- Development of monoclonal antibodies for the treatment of colorectal cancerAmerican Journal of Health-System Pharmacy, 2008
- TrastuzumabDrugs, 2007
- MUC1 Oncoprotein Stabilizes and Activates Estrogen Receptor αMolecular Cell, 2006
- MUC1 Mediates Transendothelial Migration in vitro by Ligating Endothelial Cell ICAM-1Clinical & Experimental Metastasis, 2005
- Aromatase inhibitors increase the sensitivity of human tumor cells to monocyte-mediated, antibody-dependent cellular cytotoxicityThe American Journal of Surgery, 2005
- Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancerLaboratory Investigation, 2005
- MUC1 oncoprotein is targeted to mitochondria by heregulin-induced activation of c-Src and the molecular chaperone HSP90Oncogene, 2005
- The MUC1 SEA Module Is a Self-cleaving DomainOnline Journal of Public Health Informatics, 2005
- MUC1 alters β-catenin-dependent tumor formation and promotes cellular invasionOncogene, 2003
- Antibody-dependent cell-mediated cytotoxicity can be induced by MUC1 peptide vaccination of breast cancer patientsInternational Journal of Cancer, 2001